Phase 3Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes (Enith1)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes
- Sponsor
- Hoffmann-La Roche (Industry)
- Enrolment
- 2,000 planned
- Conditions
- Obesity or Overweight
- Interventions
- Placebo; Enicepatide
- Ages
- adults, older adults
- Registry
- NCT07351045, CTIS2025-523104-71-00
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.
Primary outcomes
- Percent (%) Change from Baseline in Body Weight at Week 72
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered